3-Deoxyglucosone (Synonyms: 3-Deoxy-D-glucosone)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
3-Deoxyglucosone  (Synonyms: 3-Deoxy-D-glucosone)

3-Deoxyglucosone (3-Deoxy-D-glucosone) 是美拉德反应和多元醇途径的反应中间体 (intermediate)。3-Deoxyglucosone 与蛋白质氨基快速反应形成晚期糖基化终产物 (AGEs)，例如咪唑啉酮，它是 3-DG 的最特异 AGE。3-Deoxyglucosone 可以与低葡萄糖协同作用以增强 GLP-1 分泌，可以作为糖尿病生物学检测的标志物。

3-Deoxyglucosone (Synonyms: 3-Deoxy-D-glucosone)

3-Deoxyglucosone Chemical Structure

CAS No. : 4084-27-9

规格 价格 是否有货 数量
1 mg ￥2320 In-stock
5 mg ￥5800 In-stock
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

3-Deoxyglucosone 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes[1][2][3].

体外研究
(In Vitro)

3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour) markedly increases GLP-1 secretion by 1.23-folds in 300 ng/ml or 1000 ng/ml 3DG-treated group. But at alower concentration (80 ng/ml) has no effects[1].
3-Deoxyglucosone (300 ng/ml; 1 hour) dramatically increases intracellular Ca2+ levels by Fluo-3/AM determination (2.5 μM for 30 mins). But 3DG does not affect intracellular cAMP levels in a cAMP Elisa assay[1].
3-Deoxyglucosone (300 ng/ml; 1 hour) significantly increases the protein expression levels of TAS1R2, TAS1R3, and TRPM5 under both glucose-free and highconditions[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

3-Deoxyglucosone 相关抗体:

Western Blot Analysis[1]

Cell Line: STC-1 cells
Concentration: 300 ng/ml
Incubation Time: 1 hour
Result: Upregulated TAS1R2, TAS1R3, and TRPM5 expression.

体内研究
(In Vivo)

3-Deoxyglucosone (intragastric administration; 20 mg/kg; single dose) impairs glucose tolerance with increased AUC, but the plasma glucagon levels are not significantly different. It developes impaired glucose regulation (IGR) with obviously pancreatic islet cell dysfunction in kunming mice and SD-rats[2].
3-deoxyglucosone (gastric gavage; 5-50 mg/kg; once daily; 2 weeks) is significantly increased in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold) and colon (two fold) compared with the basal levels in the corresponding control group. In addition, the protein expressions of TAS1R2, TAS1R3 and TRPM5 in both duodenum and colon are significantly decreased[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SD rats[3]
Dosage: 5, 20 and 50 mg/kg
Administration: oral administration; once daily; 2 weeks
Result: Was capable of accumulating in intestinal tissue and thereby decreased secretion of GLP-1 and insulin.  

分子量

162.14

Formula

C6H10O5
CAS 号

4084-27-9
结构分类
  • Saccharides
初始来源
  • 内源性代谢物
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (534 KB) 产品使用指南 (1538 KB)

参考文献

  • [1]. Song X, et al. 3-Deoxyglucosone Induces Glucagon-Like Peptide-1 Secretion from STC-1 Cells via Upregulating Sweet Taste Receptor Expression under Basal Conditions.Int J Endocrinol. 2019 Oct 23;2019:4959646.  [Content Brief]

    [2]. Wang F, et al. Acute Reduction of Incretin Effect and Glucose Intolerance in Rats by Single Intragastric Administration of 3-deoxyglucosone. Exp Clin Endocrinol Diabetes. 2017 Jan;125(1):4-11.  [Content Brief]

    [3]. Zhang L, et al. Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats. Diabetol Metab Syndr. 2016 Nov 29;8:78.  [Content Brief]

    [4]. Niwa T, et al. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication.J Chromatogr B Biomed Sci Appl. 1999 Aug 6;731(1):23-36.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务